These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22436444)

  • 1. An adaptive strategy for assessing regional consistency in multiregional clinical trials.
    Chen J; Quan H; Gallo P; Ouyang SP; Binkowitz B
    Clin Trials; 2012 Jun; 9(3):330-9. PubMed ID: 22436444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
    Chen CT; Hung HM; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials.
    Wang SJ; James Hung HM
    J Biopharm Stat; 2012 Sep; 22(5):879-93. PubMed ID: 22946937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing consistency across all regions in a multi-regional clinical trial.
    Tsou HH; James Hung HM; Chen YM; Huang WS; Chang WJ; Hsiao CF
    Pharm Stat; 2012; 11(4):295-9. PubMed ID: 22504851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative consistency of treatment effects in multiregional clinical trials.
    Tanaka Y; Li G; Wang Y; Chen J
    J Biopharm Stat; 2012 Sep; 22(5):988-1000. PubMed ID: 22946945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of regional treatment effect in a multiregional clinical trial.
    Tsong Y; Chang WJ; Dong X; Tsou HH
    J Biopharm Stat; 2012 Sep; 22(5):1019-36. PubMed ID: 22946947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An optimal adaptive design to address local regulations in global clinical trials.
    Luo X; Shih WJ; Ouyang SP; Delap RJ
    Pharm Stat; 2010; 9(3):179-89. PubMed ID: 20872620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing dose-region profile of drug efficacy: a multiregional trial strategy.
    Chen YH; Wang M
    J Biopharm Stat; 2012 Sep; 22(5):894-902. PubMed ID: 22946938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian approach to evaluating regional treatment effect in a multiregional trial.
    Chen YH; Wu YC; Wang M
    J Biopharm Stat; 2009 Sep; 19(5):900-15. PubMed ID: 20183451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials.
    Liu JT; Tsou HH; Gordon Lan KK; Chen CT; Lai YH; Chang WJ; Tzeng CS; Hsiao CF
    Stat Med; 2016 Jun; 35(14):2301-14. PubMed ID: 26833851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consideration of regional difference in design and analysis of multi-regional trials.
    Hung HM; Wang SJ; O'Neill RT
    Pharm Stat; 2010; 9(3):173-8. PubMed ID: 20872619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional differences in multinational clinical trials: anticipating chance variation.
    Marschner IC
    Clin Trials; 2010 Apr; 7(2):147-56. PubMed ID: 20338904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graphical assessment of consistency in treatment effect among countries in multi-regional clinical trials.
    Chen J; Zheng H; Quan H; Li G; Gallo P; Ouyang SP; Binkowitz B; Ting N; Tanaka Y; Luo X; Ibia E;
    Clin Trials; 2013; 10(6):842-51. PubMed ID: 24013404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cautionary note on regional consistency evaluation in multiregional clinical trials with binary outcomes.
    Homma G
    Pharm Stat; 2024; 23(3):385-398. PubMed ID: 38124266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects.
    Ando Y; Uyama Y
    J Biopharm Stat; 2012 Sep; 22(5):977-87. PubMed ID: 22946944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials.
    Chen YF; Wang SJ; Khin NA; Hung HM; Laughren TP
    Pharm Stat; 2010; 9(3):217-29. PubMed ID: 20872622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials.
    Huang Y; Chang WJ; Hsiao CF
    Pharm Stat; 2013; 12(2):59-64. PubMed ID: 23319408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.